University hospital evaluates сoagulopathy and мasculopathy as a predictor of the severity of SARS-CoV-2 / COVID-19 infection

Photo by Dmitriy Suponnikov

French university hospital Assistance Publique - Hôpitaux de Paris is recruiting patients for the clinical trial of Coagulopathy and Vasculopathy Assessment as a Predictor of the Severity of SARS-CoV-2 / COVID-19 Infection (SARCODO).

On 30 January 2020, WHO declared the SARS-CoV-2 outbreak as a public health emergency of international concern. Compared to SARS-CoV, which caused an outbreak of SARS in 2003, SARS-CoV-2 has a higher transmission capacity. Although the clinical manifestations of SARS-CoV-2 are dominated by respiratory symptoms, some patients have severe cardiovascular damage. In addition, patients with underlying cardiovascular disease may be at increased risk of death. Therefore, understanding the impairments caused by SARS-CoV-2 to the cardiovascular system and the underlying mechanisms is of the utmost importance.

This project proposes to study different aspects of the diagnosis and pathophysiology of SARS-CoV-2. The researchers propose to fully study activation state of coagulation and endothelium on a plasma and cellular side in patients diagnosed with SARS-CoV-2/COVID19. The different forms of the disease will be included: without lung disease, with a more or less severe lung disease, i.e. having evolved or not towards acute respiratory distress syndrome (ARDS). Extensive research of biomarkers will be compared to the detection of the virus in the respiratory tract as well as in the blood. This work will contribute to a better description of disease pathophysiology and should allow us to identify a patient profile in whom preventive or curative anticoagulant therapy could be considered.

The patients that can be enrolled into this study include public hospital patients.

On 8 June 2020, first participant was enrolled into this clinical study.

Patients at least 18 years old, hospitalized for suspected COVID-19 in the medical wards or intensive care unit, patients benefiting from a social security scheme have the opportunity to participate in this clinical trial.

The addresses are Hôpital Cochin, Paris, France, 75014  and Hôpital Européen Georges Pompidou, Paris, France, 75015.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04624997.